More importantly, patients with CD5+ DLBCL do not benefit from rituximab-based immunochemotherapy or stem cell transplantation, with an overall survival (OS) of <30 months when treated with R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) (6, 7). Here, CD5 is linked to diffuse large B-cell lymphoma.